F. Cavalli

发表

A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma: a report of the Non-Hodgkin's Lymphoma Classification Project

B. Nathwani, W. Chan, D. Weisenburger, 1997 .

Cancer in the developing world: can we avoid the disaster?

F. Cavalli, 2006, Nature Clinical Practice Oncology.

A novel flow cytometric method for the quantification of p53 gene expression.

F. Cavalli, G. Filippini, S. Griffin, 1998, Cytometry.

Tamoxifen for early breast cancer: an overview of the randomised trials

Mike Clarke, Luc Bijnens, Michael Gnant, 1998, The Lancet.

Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.

Bruce D Cheson, Lawrence H Schwartz, Emanuele Zucca, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Y Wang, Mike Clarke, Donald A. Berry, 2005, The Lancet.

Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type.

F. Cavalli, E. Pedrinis, L. Mazzucchelli, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Informed consent for phase I studies: evaluation of quantity and quality of information provided to patients.

F. Cavalli, C. Sessa, M. Tomamichel, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

subtype-specific lesions with an impact on the clinical outcome Genome-wide DNA profiling of marginal zone lymphomas identifies

R. Gascoyne, F. Cavalli, M. Piris, 2011 .

Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome.

Francesco Bertoni, Ivo Kwee, Govind Bhagat, 2011, Blood.

Present and future projects of the international breast cancer study group

J. Forbes, F. Cavalli, R. Gelber, 1994, Cancer.

International Prognostic Score for Asymptomatic Early-stage Chronic Lymphocytic Leukemia.

E. Montserrat, F. Cavalli, M. Ghielmini, 2020, Blood.

Genome wide DNA‐profiling of HIV‐related B‐cell lymphomas

Francesco Bertoni, Ivo Kwee, Vincenzo Canzonieri, 2010, British journal of haematology.

Treatment of childhood Wilms' tumor without radiotherapy in Nicaragua.

F. Cavalli, G. Masera, V. Conter, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

Terry L. Smith, R. Collins, L. Holmberg, 1998, Lancet.

First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial.

A. López-Guillermo, F. Cavalli, H. Gómez, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Anthracycline-based chemotherapy as primary treatment for intravascular lymphoma.

A. López-Guillermo, E. Campo, F. Cavalli, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Can rituximab change the usually dismal prognosis of patients with intravascular large B-cell lymphoma?

F. Jardin, F. Cavalli, E. Zucca, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hodgkin's disease: treatment of relapsed disease.

F. Cavalli, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Matching the clinical function and symptom status with the expectations of patients with advanced cancer, their families, and health care workers

E. Bruera, F. Cavalli, H. Neuenschwander, 1997, Supportive Care in Cancer.

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Ivanov, Harris, R. Collins, 2005, The Lancet.

Pentostatin (2'-deoxycoformycin, dCF) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas: phase II study of the EORTC Early Clinical Trials Group.

F. Cavalli, M. van Glabbeke, S. Monfardini, 1996, Oncology.

Life expectancy of young adults with follicular lymphoma.

A. López-Guillermo, S. Montoto, E. Montserrat, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

A multicenter study of treatment of primary CNS lymphoma

J. Blay, F. Berger, F. Cavalli, 2002, Neurology.

Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies.

J. Gribben, F. Cavalli, T. Habermann, 2022, The Lancet. Haematology.

Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphomagenesis and microbial-targeted therapy.

F. Cavalli, J. Radford, C. Doglioni, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Metastatic colorectal cancer.

F. Cavalli, P. Saletti, 2006, Cancer treatment reviews.

Axillary apocrine carcinoma with brain metastases.

F. Cavalli, E. Gallerani, M. Ciriolo, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

International collaborations in cancer control and the Third International Cancer Control Congress

M. Coleman, F. Cavalli, L. Bisanti, 2009, Tumori.

Proposing phase I studies: patients', relatives', nurses' and specialists' perceptions.

F. Cavalli, C. Sessa, M. Tomamichel, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Current issues in phase I trials: new study designs and informed consent procedures.

F. Cavalli, C. Sessa, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II trial of Nimustine (ACNU; 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-1-(2-chloroethyl)-1-nitrosourea hydrochloride) in patients with small cell carcinoma of the lung after failure on combination chemotherapy

F. Cavalli, M. Castiglione, C. Ludwig, 2004, Investigational New Drugs.

Epirubicin in colorectal cancer

F. Cavalli, H. Hansen, H. Pinedo, 2004, Investigational New Drugs.

Phase I trial of 4-demethoxydaunorubicin (idarubicin) with single oral doses

F. Cavalli, C. Sessa, Y. Willems, 2004, Investigational New Drugs.

Phase-II study of vindesine and hexamethylmelamine in patients with relapsing small cell carcinoma of the lung

F. Cavalli, W. Jungi, R. Joss, 2004, Cancer Chemotherapy and Pharmacology.

A Phase I trial of Cis-diammine-1,1-cyclobutane dicarboxylate platinum II (Carboplatin, CBDCA, JM-8) with a single dose every five week-schedule

F. Cavalli, A. Goldhirsch, C. Sessa, 2004, Investigational New Drugs.

Phase I trial of 4′-deoxydoxorubicin given weekly

F. Cavalli, C. Sessa, L. Bosia, 2004, Investigational New Drugs.

A clinical trial of aminoglutethimide in advanced postmenopausal breast carcinoma: low response in patients previously treated with medroxyprogesterone.

F. Cavalli, A. Goldhirsch, J. Obrecht, 1985, European journal of cancer & clinical oncology.

Combination chemotherapy with cisplatin, methotrexate, bleomycin, and vincristine (CABO) in advanced squamous cell carcinoma of the head and neck

F. Cavalli, M. Rozencweig, P. Dodion, 1984, Cancer.

Targeted therapy in lymphoma

F. Cavalli, T. Witzig, R. Yuan, 2010, Journal of hematology & oncology.

Molecular follow-up in gastric mucosa-associated lymphoid tissue lymphomas: early analysis of the LY03 cooperative trial.

F. Cavalli, E. Pedrinis, R. Souhami, 2002, Blood.

Resources-Stratified Guidelines for Classical Hodgkin Lymphoma

G. Salles, J. Connors, F. Cavalli, 2020, International journal of environmental research and public health.

Extranodal involvement Hodgkin’s lymphoma

V. Diehl, F. Cavalli, M. Fuchs, 2008 .

Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial

F. Cavalli, J. Panse, M. Falautano, 2022, Leukemia.

Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study*

F. Cavalli, H. van de Velde, Jie Jin, 2019, Leukemia & lymphoma.

Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the randomized, phase 3 LYM-3002 study

F. Cavalli, J. Novak, J. Zaucha, 2018, Leukemia & lymphoma.

Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial.

F. Cavalli, F. Angrilli, V. Torri, 2017, The Lancet. Haematology.

Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study

F. Cavalli, H. van de Velde, J. Drach, 2017, Haematologica.

Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.

F. Cavalli, V. Torri, J. Panse, 2016, The Lancet. Haematology.

Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41) AMIEE.JACKSON, a MICHAELMIAN, c,d CHRISTINAKALPADAKIS, e GERASSIMOSA.PANGALIS, f ANASTASIOSSTATHIS, g ELENAPORRO, g ANNARITACONCONI, h

C. Copie-Bergman, E. Campo, F. Cavalli, 2015 .

Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41).

C. Copie-Bergman, E. Campo, F. Cavalli, 2015, The oncologist.

Histologic transformation in marginal zone lymphomas†.

F. Cavalli, L. Mazzucchelli, G. Gaidano, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Incidence, risk factors and outcome of histological transformation in follicular lymphoma

F. Cavalli, M. Ghielmini, L. Mazzucchelli, 2012, British journal of haematology.

High response rate and improvement of long-term survival with combined treatment modalities in patients with poor-risk primary thyroid diffuse large B-cell lymphoma: an International Extranodal Lymphoma Study Group and Intergruppo Italiano Linfomi study

A. López-Guillermo, F. Cavalli, A. Rossi, 2011, Leukemia & lymphoma.

Patterns of survival of follicular lymphomas at a single institution through three decades

F. Cavalli, M. Ghielmini, L. Mazzucchelli, 2010, Leukemia & lymphoma.

Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma.

J. Armitage, E. Thiel, F. Cavalli, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Etoposide, cisplatin and doxorubicin in patients with small cell lung cancer: tumor response and long term survival.

F. Cavalli, R. Joss, J. Obrecht, 1986, European journal of cancer & clinical oncology.

The gastric marginal zone B-cell lymphoma of MALT type.

F. Cavalli, E. Zucca, F. Bertoni, 2000, Blood.

Treatment of Pediatric non‐Hodgkin lymphomas in a country with limited resources: Results of the first national protocol in Nicaragua

F. Cavalli, G. Masera, M. Pillon, 2008, Pediatric blood & cancer.

Primary pulmonary lymphoma: current status.

F. Cavalli, L. Wannesson, E. Zucca, 2005, Clinical lymphoma & myeloma.

Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue.

A. López-Guillermo, E. Campo, F. Cavalli, 2003, Blood.

HIV-testing and Newly-diagnosed Malignant Lymphomas. The SAKK 96/90 Registration Study

F. Cavalli, R. Stahel, J. Torhorst, 2003, Leukemia & lymphoma.

Primary extranodal non-Hodgkin's lymphomas. Part 1: Gastrointestinal, cutaneous and genitourinary lymphomas.

F. Cavalli, E. Zucca, F. Bertoni, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomis

F. Cavalli, Jie Jin, J. Drach, 2018, The Lancet. Oncology.

Tackling cancer: time for a global response

F. Cavalli, 2016, The Lancet.

Current status and perspectives in the treatment of non-Hodgkin's lymphomas.

F. Cavalli, H. Honegger, 1984, European journal of cancer & clinical oncology.

Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non‐Hodgkin's lymphoma

F. Cavalli, G. Martinelli, F. Bertolini, 2003, British journal of haematology.

Pathobiology of Primary Mediastinal B-Cell Lymphoma

P. Gaulard, F. Cavalli, S. Pileri, 2003, Leukemia & lymphoma.

Treatment of extranodal lymphomas.

F. Cavalli, E. Zucca, A. Conconi, 2002, Best practice & research. Clinical haematology.

Prevalence of Helicobacter pylori and hepatitis C virus infections among non-Hodgkin's lymphoma patients in Southern Switzerland.

F. Cavalli, E. Pedrinis, E. Zucca, 2000, Haematologica.

Molecular detection of circulating neoplastic cells in patients with clinically localised gastric and non-gastric mucosa-associated lymphoid tissue lymphoma.

F. Cavalli, E. Zucca, F. Bertoni, 2000, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Association of gastric and Waldeyer's ring lymphoma: a molecular study

F. Cavalli, E. Pedrinis, M. Tinguely, 2000, Hematological oncology.

BCL10 gene mutations rarely occur in lymphoid malignancies

F. Cavalli, L. Cro, L. Baldini, 2000, Leukemia.

Clonality assessment in blood of patients with mantle cell lymphoma.

F. Cavalli, E. Pedrinis, E. Zucca, 1999, Leukemia & lymphoma.

High incidence of other neoplasms in patients with low-grade gastric MALT lymphoma.

F. Cavalli, E. Pedrinis, A. Pascarella, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

North-South twinning in paediatric haemato-oncology: the La Mascota programme, Nicaragua

F. Cavalli, G. Tognoni, G. Masera, 1998, The Lancet.

My child matters program: A UICC-sanofi-aventis partnership to improve pediatric cancer care in developing countries

E. Steliarova-Foucher, F. Cavalli, R. Ribeiro, 2007 .

Defining clinical benefit in postmenopausal patients with breast cancer under second-line endocrine treatment: does quality of life matter?

F. Cavalli, A. Goldhirsch, C. Hürny, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SAKK)

F. Cavalli, A. Goldhirsch, M. Castiglione, 1997, European journal of cancer.

Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group.

F. Cavalli, P. Roy, M. Gospodarowicz, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Granulocyte growth factors: achieving a consensus.

F. Cavalli, J. Gatell, D. Khayat, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

Low prevalence of Chlamydia psittaci in ocular adnexal lymphomas from Cuban patients

F. Cavalli, L. Mazzucchelli, E. Zucca, 2007, Leukemia & lymphoma.

Emerging Role of Infectious Etiologies in the Pathogenesis of Marginal Zone B-cell Lymphomas

F. Cavalli, E. Zucca, F. Bertoni, 2014, Clinical Cancer Research.

MALT lymphoma: extranodal marginal zone B-cell lymphoma of MALT

F. Cavalli, A. Stathis, E. Zucca, 2013 .

Pathogenesis and treatment of extranodal lymphomas: the fascinating model of mucosa-associated lymphoid tissue lymphoma.

F. Cavalli, E. Zucca, F. Bertoni, 2003, Haematologica.

Molecular analysis of the progression from Helicobacter pylori-associated chronic gastritis to mucosa-associated lymphoid-tissue lymphoma of the stomach.

F. Cavalli, E. Pedrinis, E. Zucca, 1998, The New England journal of medicine.

Immunoglobulin heavy chain Diversity genes rearrangement pattern indicates that MALT‐type gastric lymphoma B cells have undergone an antigen selection process

F. Cavalli, E. Pedrinis, E. Zucca, 1997, British journal of haematology.

Reply to B. Bennani-Baiti et al, H.J.A. Adams et al, E. Laffon et al, and E.A. Hawkes et al.

F. Cavalli, T. Lister, R. Fisher, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Changing the landscape of European School of Oncology–European Society for Medical Oncology masterclasses in clinical oncology during the COVID-19 pandemic

F. Cavalli, F. Lordick, M. Aapro, 2022, Future oncology.

Eight-Year Experience of the Certificate of Competence and Advanced Studies Program Organized by the European School of Oncology

F. Cavalli, N. Pavlidis, F. Peccatori, 2021, Journal of cancer education : the official journal of the American Association for Cancer Education.

Should intra-cerebrospinal fluid prophylaxis be part of initial therapy for patients with non-Hodgkin lymphoma: what we know, and how we can find out more.

F. Cavalli, C. Gisselbrecht, U. Schlegel, 2009, Seminars in oncology.

NAD(P)H:quinone oxidoreductase 1 expression in human primary melanotic melanomas of the skin.

F. Cavalli, F. Zappa, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of amsacrine in solid tumors: a report of the EORTC Early Clinical Trial-Group.

F. Cavalli, M. van Glabbeke, H. Hansen, 1983, European journal of cancer & clinical oncology.

Promoter methylation patterns in Richter syndrome affect stem‐cell maintenance and cell cycle regulation and differ from de novo diffuse large B‐cell lymphoma

F. Berger, F. Cavalli, D. Rossi, 2013, British journal of haematology.

Genome-wide DNA proﬁling of marginal zone lymphomas identiﬁes subtype-speciﬁc lesions with an impact on the clinical outcome

R. Gascoyne, F. Cavalli, M. Piris, 2011 .

Genetic alterations underlying the pathogenesis of MALT lymphoma.

F. Cavalli, E. Zucca, F. Bertoni, 2002, The hematology journal : the official journal of the European Haematology Association.

Clinical Lymphoma & Myeloma November 2005 Primary Pulmonary Lymphoma

F. Cavalli, E. Zucca, L. Wannesson, 2022 .

Hepatitis C virus and GBV‐C virus prevalence among patients with B‐cell lymphoma in different European regions: a case‐control study of the International Extranodal Lymphoma Study Group

A. López-Guillermo, E. Montserrat, F. Cavalli, 2012, Hematological oncology.

Psycho-Oncology and Communication

J. Armitage, F. Cavalli, H. Hansen, 2009 .

The development of liquid biopsy for research and clinical practice in lymphomas: Report of the 15‐ICML workshop on ctDNA

W. Wilson, F. Cavalli, D. Kurtz, 2019, Hematological oncology.

Genetic and Phenotypic Attributes of Splenic Marginal Zone Lymphoma.

A. López-Guillermo, F. Cavalli, A. Elia, 2021, Blood.

Stage-modified international prognostic index effectively predicts clinical outcome of localized primary gastric diffuse large B-cell lymphoma. International Extranodal Lymphoma Study Group (IELSG)

F. Cavalli, T. Barbui, A. Rossi, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Management of lymphomas at extranodal locations

F. Cavalli, E. Zucca, A. Conconi, 2010 .

The addition of rituximab to anthracycline‐based chemotherapy significantly improves outcome in ‘Western’ patients with intravascular large B‐cell lymphoma

F. Cavalli, R. Soffietti, C. Doglioni, 2008, British journal of haematology.

Definition, diagnosis, and management of intravascular large B-cell lymphoma: proposals and perspectives from an international consensus meeting.

E. Campo, F. Cavalli, S. Pileri, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Variations in clinical presentation, frequency of hemophagocytosis and clinical behavior of intravascular lymphoma diagnosed in different geographical regions.

E. Campo, F. Cavalli, S. Ascani, 2007, Haematologica.

Hormones in Cancer Treatment

F. Cavalli, 1989 .

Reactive perivascular T‐cell infiltrate predicts survival in primary central nervous system B‐cell lymphomas

J. Blay, F. Berger, F. Cavalli, 2007, British journal of haematology.

Feasibility of quality of life assessment in a randomized phase III trial of small cell lung cancer--a lesson from the real world--the Swiss Group for Clinical Cancer Research SAKK.

F. Cavalli, C. Hürny, J. Bernhard, 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

AROME-ESO Oncology Consensus Conference: access to cancer care innovations in countries with limited resources. Association of Radiotherapy and Oncology of the Mediterranean Area (AROME-Paris) and European School of Oncology (ESO - Milan).

F. Cavalli, A. Kuten, M. Aapro, 2019, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial.

F. Cavalli, C. Doglioni, E. Zucca, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial

F. Cavalli, A. Brandes, G. Avvisati, 2009, The Lancet.

The clinical training centers fellowships: a European School of Oncology career development program (2013-2019).

F. Cavalli, M. Aapro, Alberto Costa, 2020, Future oncology.

A phase II study of cisplatin in advanced gastric cancer.

F. Cavalli, G. Cocconi, M. Varini, 1983, European journal of cancer & clinical oncology.

Double-blind randomized study on the myeloprotective effect of melatonin in combination with carboplatin and etoposide in advanced lung cancer

F. Cavalli, M. Ghielmini, C. Sessa, 1999, British Journal of Cancer.

Commentary 2008: 25 or 50 years later?

F. Cavalli, C. Sessa, P. Saletti, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Morphologic, Immunophenotypic and in Vitro Growth Characteristics of Blood and Bone Marrow Associated with Stem Cell Mobilisation in Patients with Lymphoma

F. Cavalli, M. Ghielmini, S. Pampallona, 2000, Leukemia & lymphoma.

Distribution of mobilized progenitor cells in the buffy coat of the haemonetics MCS3p cell separator: a study to optimize the collection of progenitors by leukapheresis.

F. Cavalli, M. Ghielmini, E. Zucca, 1998, Journal of Hematotherapy.

Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: Phase II randomized study comparing two dose levels

F. Cavalli, R. Dummer, L. Heinzerling, 2002, Cancer Gene Therapy.

International Collaborative Group against Primary CNS Lymphomas.

J. Armitage, F. Cavalli, T. Batchelor, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and clinical pharmacological evaluation of aphidicolin glycinate.

F. Cavalli, M. Zucchetti, C. Sessa, 1991, Journal of the National Cancer Institute.

Enzymuria in Carboplatin Nephrotoxicity

F. Cavalli, C. Sessa, E. Zucca, 1987, Tumori.

Report on the International Workshop on Staging and Treatment of Testicular Cancer.

F. Cavalli, S. Monfardini, G. Pizzocaro, 1980, European journal of cancer.

Phase II study of 9-hydroxy-2N-methylellipticinium acetate.

F. Cavalli, H. Hansen, A. Brugarolas, 1984, European Journal of Cancer and Clinical Oncology.

Concurrent or sequential use of cytotoxic chemotherapy and hormone treatment in advanced breast cancer: report of the Swiss Group for Clinical Cancer Research.

F. Cavalli, W. Jungi, K. Brunner, 1983, British medical journal.

High-dose chemotherapy with autologous stem cell transplantation is feasible and safe in a regional hospital. A 6-year experience in southern Switzerland

F. Cavalli, M. Ghielmini, A. Goldhirsch, 1997, Bone Marrow Transplantation.

Phase II study of iproplatin in advanced ovarian carcinoma.

F. Cavalli, D. Smith, C. Sessa, 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cardiac involvement in HIV-related non-Hodgkin's lymphoma: a case report and short review of the literature

F. Cavalli, E. Pedrinis, E. Zucca, 1998, Annals of Hematology.

Simultaneous occurrence of peripheral T-cell lymphoma unspecified and B-cell small lymphocytic lymphoma. Report of 2 cases.

F. Cavalli, S. Pileri, L. Mazzucchelli, 2007, Human pathology.

Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience.

J. Blay, F. Berger, F. Cavalli, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the ‘cutaneous variant’ 1

A. López-Guillermo, E. Campo, F. Cavalli, 2004, British journal of haematology.

Addition of Thiotepa and Rituximab to Antimetabolites Significantly Improves Outcome in Primary CNS Lymphoma: First Randomization of the IELSG32 Trial.

F. Cavalli, R. Soffietti, M. Reni, 2015, Clinical advances in hematology & oncology : H&O.

Ten years of international primary CNS lymphoma collaborative group studies.

J. Armitage, F. Cavalli, T. Batchelor, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Virtual Tissue Bank for Primary Central Nervous System Lymphomas in Immunocompetent Individuals

F. Cavalli, L. Mazzucchelli, C. Doglioni, 2007, Pathobiology.

Original article: CGS 16949A, a new aromatase inhibitor in the treatment of breast cancer — A Phase I study

F. Cavalli, A. Bhatnagar, K. Hoeffken, 1990 .

Treatment of childhood Hodgkin's disease with COPP or COPP-ABV (hybrid) without radiotherapy in Nicaragua.

F. Cavalli, C. Sessa, G. Masera, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Malignant Lymphomas and Hodgkin’s Disease: Experimental and Therapeutic Advances

F. Cavalli, G. Bonadonna, M. Rozencweig, 2011, Developments in Oncology.

Relevance of intraocular involvement in the management of primary central nervous system lymphomas.

J. Blay, F. Berger, F. Cavalli, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Nodal marginal zone B-cell lymphomas may arise from different subsets of marginal zone B lymphocytes.

F. Cavalli, E. Pedrinis, E. Zucca, 2001, Blood.

Non-Hodgkin Lymphoma

Randy D Gascoyne, J. Armitage, R. Gascoyne, 2016, Precision Haematological Cancer Medicine.

Thrombotic thrombocytopenic purpura associated with renal failure after autologous transplantation for multiple myeloma successfully treated with rituximab

F. Cavalli, A. Stathis, E. Romagnani, 2006, European journal of haematology.

Review Primary extranodal non-Hodgkin's lymphomas. Part IT Gastrointestinal, cutaneous and genitourinarylymphomas

F. Cavalli, F. Bertoni, E. Zucca, 2005 .

Clinical relevance of bcl-2(MBR)/J(H) rearrangement detected by polymerase chain reaction in the peripheral blood of patients with follicular lymphoma.

F. Cavalli, E. Zucca, F. Bertoni, 1997, British Journal of Cancer.

Hodgkin's and Castleman's disease in a patient with systemic mastocytosis

F. Cavalli, E. Pedrinis, M. Ghielmini, 1999, Annals of Hematology.

Primary extranodal non-Hodgkin's lymphomas. Part 2: Head and neck, central nervous system and other less common sites.

F. Cavalli, E. Zucca, F. Bertoni, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

IELSG-38: A Phase II Study of Chlorambucil in Combination with Rituximab Followed By Maintenance Therapy with Subcutaneous Rituximab in Patients with Extranodal Marginal Zone B-Cell Lymphoma of Mucosa Associated Lymphoid Tissue (MALT)

F. Cavalli, B. Coiffier, H. Tilly, 2017 .

Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy.

G. Salles, E. Campo, F. Cavalli, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bortezomib-based therapy for mantle-cell lymphoma.

F. Cavalli, 2015, The New England journal of medicine.

Rare syndromes in Hodgkin's disease.

F. Cavalli, 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

Palliative care of cancer patients: audit of current hospital procedures

F. Cavalli, C. Sessa, H. Neuenschwander, 1998, Supportive Care in Cancer.

Phase Ii trial of fotemustine in advanced colorectal cancer.

F. Cavalli, H. Bleiberg, B. Gerard, 1990, European journal of cancer.

A randomized comparison of doxifluridine and fluorouracil in colorectal carcinoma.

F. Cavalli, R. Joss, W. Weber, 1988, European journal of cancer & clinical oncology.

Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII.

F. Cavalli, M. Bonetti, R. Gelber, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of oral VP-16-213 in hepatocellular carcinoma.

F. Cavalli, H. Hansen, A. Goldhirsch, 1981, European journal of cancer & clinical oncology.

CancerWorld Template

F. Cavalli, M. Gospodarowicz, 2017 .

Chemotherapy of Testicular Cancer: From Palliation to Cure

F. Cavalli, 1983 .

Estimation of the haematological toxicity of minor groove alkylators using tests on human cord blood cells.

F. Cavalli, M. Ghielmini, V. Torri, 1997, British Journal of Cancer.

A phase I trial of inotuzumab ozogamicin in combination with temsirolimus in patients with relapsed or refractory CD22-positive B-cell non-Hodgkin lymphomas

F. Cavalli, L. Mazzucchelli, A. Stathis, 2021, Leukemia & lymphoma.

The Contribution of the European School Of Oncology Education to the Central Asian and Caucasian Regions

F. Cavalli, Alberto Costa, N. Pavlidis, 2021, Journal of cancer education : the official journal of the American Association for Cancer Education.

myeloid leukemia A phase II clinical study of SU5416 in patients with refractory acute

F. Cavalli, D. Hossfeld, U. Dührsen, 2013 .

Detection of chromosome 11 alterations in blood and bone marrow by interphase cytogenetics in mantle cell lymphoma

F. Cavalli, G. Soldati, E. Zucca, 1995, British journal of haematology.

Clinical significance of bcl-2 (MBR)/JH rearrangement in the peripheral blood of patients with diffuse large B-cell lymphomas.

F. Cavalli, E. Pedrinis, E. Zucca, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

535 Randomized trial of low vs. High dose medroxyprogesterone acetate (MPA) in the treatment of post-menopausal patients with advanced breast cancer

F. Cavalli, A. Goldhirsch, P. Schafer, 1983 .

VP-16 in the treatment of malignant lymphomas: a report from the Swiss Group for Clinical Cancer Research (SAKK).

F. Cavalli, 1985, Seminars in oncology.

Fewer infections, but maintained antitumor activity with lower-dose versus standard-dose cladribine in pretreated low-grade non-Hodgkin's lymphoma.

F. Cavalli, R. Herrmann, M. Fey, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Improved outcome with addition of thiotepa and rituximab to methotrexate and cytarabine in primary cns lymphoma: Results of the first randomization of the IELSG-32 trial

A. Ferrer, F. Cavalli, R. Soffietti, 2015 .

Efficacy and Toxicity of the Angiogenesis Inhibitor SU 5416 As a Single Agent in Patients with Advanced Renal Cell Carcinoma , Melanoma , and Soft Tissue Sarcoma 1

F. Cavalli, A. Harris, J. Baselga, 2003 .

Dose-finding study of paclitaxel and cyclophosphamide in women with advanced breast cancer.

F. Cavalli, A. Goldhirsch, G. Martinelli, 1997, Seminars in oncology.

Dose-finding study of paclitaxel and cyclophosphamide in patients with advanced breast cancer.

F. Cavalli, A. Goldhirsch, C. Sessa, 1995, Seminars in oncology.

Childhood acute lymphoblastic leukemia in Nicaragua: Long‐term results in the context of an international cooperative program

G. Lucchini, F. Cavalli, M. Valsecchi, 2014, Pediatric blood & cancer.

New agents for Hodgkin’s and non-Hodgkin’s lymphomas

F. Cavalli, M. Rozencweig, A. Louie, 1985 .

Mediastinal mature teratoma with an immature component--what about the treatment?

F. Cavalli, E. Romagnani, E. Gallerani, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

From Palliation to Cure

F. Cavalli, 1983 .

Phase-II study with cis-dichlorodiammineplatinum (II) in small cell anaplastic bronchogenic carcinoma.

F. Cavalli, A. Goldhirsch, M. Beer, 1980, European journal of cancer.

Original article Docetaxel (Taxotere®)-cisplatin (TC): An effective drug combination in gastric carcinoma

F. Cavalli, M. Castiglione, M. Aapro, 2005 .

Genotyping of Classical Hodgkin Lymphoma on the Liquid Biopsy

F. Cavalli, S. Hohaus, D. Rossi, 2017 .

Detection of bcl-2/JH rearrangement in follicular and diffuse lymphoma: concordant results of peripheral blood and bone marrow analysis at diagnosis.

F. Cavalli, R. Yuan, E. Zucca, 1993, British Journal of Cancer.

Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies.

J. Gribben, F. Cavalli, T. Habermann, 2018, The Lancet. Haematology.

Phase I study of the antifolate N10-propargyl-5,8-dideazafolic acid, CB 3717.

F. Cavalli, M. Zucchetti, C. Sessa, 1988, European journal of cancer & clinical oncology.

Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin’s lymphoma

J. Briones, G. Salles, F. Cavalli, 2013, Haematologica.

Sequential estrogen receptor determinations from primary breast cancer and at relapse: prognostic and therapeutic relevance. The International Breast Cancer Study Group (formerly Ludwig Group).

F. Cavalli, R. Gelber, A. Goldhirsch, 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of doxifluridine in advanced squamous cell carcinoma of the head and neck.

F. Cavalli, E. Kaplan, R. Abele, 1984, European journal of cancer & clinical oncology.

Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function.

F. Cavalli, M. Zucchetti, C. Sessa, 1986, Cancer research.

Phase II study of 5′-deoxy-5-fluorouridine (doxifluridine) in advanced malignant melanoma

F. Cavalli, S. Gundersen, H. Pinedo, 2004, Cancer Chemotherapy and Pharmacology.

A phase II study of doxifluridine in patients with advanced breast cancer.

F. Cavalli, W. Jungi, G. Decoster, 1988, European journal of cancer & clinical oncology.

Phase II study of doxifluridine in advanced colorectal adenocarcinoma.

F. Cavalli, P. Alberto, E. Holdener, 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cisplatin and vindesine combination chemotherapy in advanced malignant melanoma: an EORTC phase II study.

F. Cavalli, J. Mulder, M. Rozencweig, 1982, European journal of cancer & clinical oncology.

Post-remission therapy of adult acute myeloid leukaemia: one cycle of high-dose versus standard-dose cytarabine. Leukaemia Project Group of the Swiss Group for Clinical Cancer Research (SAKK).

F. Cavalli, M. Fey, A. Gratwohl, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Understanding Immune Thrombocytopenia: Looking Out of the Box

F. Cavalli, B. Godeau, T. Kühne, 2021, Frontiers in Medicine.

Pharmacokinetics of VP16-213 given by different administration methods

F. Cavalli, C. Sessa, M. D’Incalci, 2004, Cancer Chemotherapy and Pharmacology.

A phase II study of oral VP-16-213 in non-seminomatous testicular cancer.

F. Cavalli, P. Alberto, O. Klepp, 1981, European journal of cancer.

Adenocarcinoma of the rete testis.

F. Cavalli, C. Sessa, V. Spataro, 2000, The Journal of urology.

A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia.

F. Cavalli, D. Hossfeld, W. Berdel, 2003, Blood.

Dianhydrogalactitol (NSC-132313): phase II study in solid tumors.

F. Cavalli, H. Hansen, A. Brugarolas, 1979, European Journal of Cancer.

Phase II study of anhydro-ara-5-fluorocytidine in adenocarcinoma of gastrointestinal tract, epidermoid carcinoma of lung, head and neck, breast carcinoma and small cell anaplastic carcinoma of lung. A study report of the E.O.R.T.C. early clinical trial cooperative group.

F. Cavalli, H. Hansen, R. Sylvester, 1978, European journal of cancer.

Eradication of Helicobacter pylori Infection in Primary Low-Grade Gastric Lymphoma of Mucosa-Associated Lymphoid Tissue

F. Cavalli, E. Pedrinis, A. Pascarella, 1995, Annals of Internal Medicine.

Combination chemotherapy for terminal-phase chronic granulocytic leukemia: cancer and leukemia group B studies.

F. Cavalli, T. Pajak, K. Rai, 1980, Blood.

Triplex DNA-mediated downregulation of Ets2 expression results in growth inhibition and apoptosis in human prostate cancer cells.

F. Cavalli, A. Valentini, D. Watson, 2004, Nucleic acids research.

The changing paradigm of chronic lymphocytic leukemia management.

F. Cavalli, E. Zucca, F. Bertoni, 2013, European journal of internal medicine.

Extranodal Marginal Zone B-Cell Lymphoma Genotyping by Alu — Polymerase Chain Reaction

F. Cavalli, M. Broggini, E. Zucca, 2000, Leukemia & lymphoma.

Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma.

F. Cavalli, M. Ghielmini, L. Larocca, 2018, Blood.

Primary mediastinal B-cell lymphoma: high frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB.1, and PU.1 in the absence of immunoglobulins.

P. Gaulard, F. Cavalli, S. Pileri, 2003, The American journal of pathology.

European Code against Cancer 4th Edition: 12 ways to reduce your cancer risk.

Witold Zatonski, Jane Wardle, Nereo Segnan, 2015, Cancer epidemiology.

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

F. Cavalli, L. Mazzucchelli, F. Molinari, 2007, British Journal of Cancer.

METHOTREXATE/NITROUS-OXIDE TOXIC INTERACTION IN PERIOPERATIVE CHEMOTHERAPY FOR EARLY BREAST CANCER

F. Cavalli, R. Gelber, A. Goldhirsch, 1987, The Lancet.

Phase I clinical and pharmacokinetic study of oral etoposide phosphate.

F. Cavalli, M. Zucchetti, C. Sessa, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Large genomic aberrations detected by SNP array are independent prognosticators of a shorter time to first treatment in chronic lymphocytic leukemia patients with normal FISH.

F. Cavalli, D. Rossi, G. Gaidano, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Del(13q14.3) length matters: an integrated analysis of genomic, fluorescence in situ hybridization and clinical data in 169 chronic lymphocytic leukaemia patients with 13q deletion alone or a normal karyotype

F. Cavalli, D. Rossi, G. Gaidano, 2012, Hematological oncology.

Deregulation of ETS1 and FLI1 contributes to the pathogenesis of diffuse large B-cell lymphoma.

W. Chan, T. Greiner, F. Cavalli, 2013, Blood.

Chapter 21 – Marginal Zone B-Cell Lymphomas

F. Cavalli, E. Zucca, F. Bertoni, 2006 .

Taxotere is active in advanced gastric carcinoma: Results of a phase II clinical trial

F. Cavalli, J. Wanders, S. Kaye, 1993 .

Immunoglobulin heavy chain genes somatic hypermutations and chromosome 11q22‐23 deletion in classic mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research

F. Cavalli, M. Ghielmini, L. Baldini, 2004, British journal of haematology.

Microsatellite instability: application in hereditary non-polyposis colorectal cancer.

F. Cavalli, W. Atkin, K. Pack, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

LYMPHOID NEOPLASIA Deregulation of ETS 1 and FLI 1 contributes to the pathogenesis of diffuse large B-cell lymphoma

W. Chan, T. Greiner, F. Cavalli, 2013 .

Phase I study of the novel distamycin derivative tallimustine (FCE 24517).

F. Cavalli, C. Sessa, M. Strolin Benedetti, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study.

A. López-Guillermo, S. Montoto, F. Cavalli, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The gastric marginal zone B-cell lymphoma of MALT type

F. Cavalli, E. Zucca, F. Bertoni, 2000 .

Eradication of Borrelia burgdorferi infection in primary marginal zone B-cell lymphoma of the skin.

F. Cavalli, E. Pedrinis, P. Isaacson, 2000, Human pathology.

Mantle cell lymphoma

F. Cavalli, E. Zucca, F. Bertoni, 2004, Current opinion in hematology.

Patterns of survival in mantle cell lymphoma.

F. Cavalli, E. Pedrinis, E. Zucca, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

Lack of effect of cisplatin on i. v. L-PAM plasma pharmacokinetics in ovarian cancer patients

F. Cavalli, M. Zucchetti, C. Sessa, 1988, Cancer Chemotherapy and Pharmacology.

Differential expression of testin and survivin in breast cancer subtypes.

F. Cavalli, C. Catapano, M. Sarti, 2013, Oncology reports.

The impact of the European School of Oncology masterclass in clinical oncology on self-professional development.

F. Cavalli, M. Aapro, Alberto Costa, 2020, Critical reviews in oncology/hematology.

Is escalated BEACOPP a standard therapy for advanced Hodgkin's disease?

V. Diehl, F. Cavalli, J. Franklin, 2000, The hematology journal : the official journal of the European Haematology Association.

ChlVPP/ABV-VP16 hybrid regimen for advanced Hodgkin's disease: a study in 36 patients.

F. Cavalli, G. Martinelli, E. Zucca, 1999, Leukemia & lymphoma.

Lymphoma classification--the gap between biology and clinical management is closing.

W Hiddemann, J. Armitage, F. Cavalli, 1996, Blood.

Angiotropic (Intravascular) Large Cell Lymphoma: Case Report and Short Discussion of the Literature

F. Cavalli, E. Pedrinis, E. Zucca, 1997, Tumori.

All Men Are Created Equal: Addressing Disparities in Prostate Cancer Care.

F. Cavalli, D. George, S. Gillessen, 2019, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Early progression of disease predicts shorter survival in MALT lymphoma patients receiving systemic treatment.

F. Cavalli, V. Torri, L. Cascione, 2020, Haematologica.

A MALT lymphoma prognostic index.

F. Cavalli, B. Coiffier, V. Torri, 2017, Blood.

Clinical activity of bortezomib in relapsed/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG).

A. López-Guillermo, F. Cavalli, P. Zinzani, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

IV. Anti-Oestrogens in the Treatment of Advanced Breast Cancer 17. Tamoxifen in Advanced Breast Cancer: Experience of the SAKK (Schweizerische Arbeitsgruppe fur Klinische Krebsforschung - Swiss Cooperative Oncology Groupy

F. Cavalli, P. Alberto, W. Jungi, 1980 .

Tamoxifen in advanced breast cancer: experience of the SAKK (Schweizerische Arbeitsgruppe für Klinische Krebsforschung--Swiss Cooperative Oncology Group).

F. Cavalli, P. Alberto, W. Jungi, 1980, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[Prostaglandin E2 liberation in the synovial fluid induced by organo-iodinated contrast media. Interrelations with the genesis of post-arthrographic pain].

F. Cavalli, M. Cisternino, L. Bacarini, 1987, La Radiologia medica.

Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type.

F. Cavalli, B. Coiffier, E. Pedrinis, 2003, Blood.

Mantle cell lymphoma: new treatments targeted to the biology.

F. Cavalli, M. Ghielmini, E. Zucca, 2002, Clinical lymphoma.

Prednimustine: the rationale for clinical development.

F. Cavalli, P. Schein, 1986, Seminars in oncology.

Combination chemotherapy with mitomycin, vindesine, and cisplatin for non‐small cell lung cancer association of antitumor activity with initial tumor burden and treatment center

F. Cavalli, R. Stahel, H. Senn, 1990, Cancer.

Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients.

F. Cavalli, S. Pileri, M. Federico, 2002, Haematologica.

Update on the molecular biology of mantle cell lymphoma

F. Cavalli, E. Zucca, F. Bertoni, 2006, Hematological oncology.

Primary follicular and marginal-zone lymphoma of the breast: clinical features, prognostic factors and outcome: a study by the International Extranodal Lymphoma Study Group.

F. Cavalli, A. Taghian, G. Pruneri, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Menstrual cycle and timing of breast surgery in premenopausal node-positive breast cancer : Results of the International Breast Cancer Study Group ( IBCSG ) Trial

F. Cavalli, A. Goldhirsch, M. Castiglione, 2005 .

The modified International Prognostic Index can predict the outcome of localized primary intestinal lymphoma of both extranodal marginal zone B‐cell and diffuse large B‐cell histologies

F. Cavalli, H. Gómez, T. Barbui, 2002, British journal of haematology.

Intensification of salvage treatment with high‐dose sequential chemotherapy improves the outcome of patients with refractory or relapsed aggressive non‐Hodgkin's lymphoma

F. Cavalli, M. Ghielmini, T. Barbui, 2001, British Journal of Haematology.

Menstrual cycle and timing of breast surgery in premenopausal node-positive breast cancer: results of the International Breast Cancer Study Group (IBCSG) Trial VI.

F. Cavalli, A. Goldhirsch, M. Castiglione, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

First isolated locoregional recurrence following mastectomy for breast cancer: results of a phase III multicenter study comparing systemic treatment with observation after excision and radiation. Swiss Group for Clinical Cancer Research.

F. Cavalli, A. Goldhirsch, M. Castiglione, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Iproplatin and carboplatin induced toxicities: overview of phase II clinical trial conducted by the EORTC Early Clinical Trials Cooperative Group (ECTG).

F. Cavalli, M. van Glabbeke, M. Glabbeke, 1988, European journal of cancer & clinical oncology.

Marginal zone lymphomas.

F. Cavalli, A. Stathis, E. Zucca, 2008, Hematology/oncology clinics of North America.

Intrapatient Comparison of an Intermittent and a Continous Flow Cell Separator for the Collection of Progenitor and Stem Cells from the Blood

F. Cavalli, M. Ghielmini, D. Castelli, 1998, Vox Sanguinis.

The effect of adjuvant prednisone combined with CMF on patterns of relapse and occurrence of second malignancies in patients with breast cancer. International (Ludwig) Breast Cancer Study Group.

J. Forbes, F. Cavalli, R. Gelber, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Childhood acute promyelocytic leukemia in Nicaragua.

F. Cavalli, C. Sessa, G. Masera, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.

F. Cavalli, Jie Jin, J. Drach, 2015, The New England journal of medicine.

Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002.

J. Armitage, J. Blay, F. Cavalli, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dose-finding study of paclitaxel and cyclophosphamide in advanced breast cancer.

F. Cavalli, A. Goldhirsch, G. Martinelli, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study.

C. Copie-Bergman, F. Jardin, A. López-Guillermo, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cancer Prevention and Interception: A New Era for Chemopreventive Approaches

Alberto Costa, F. Cavalli, Alberto Costa, 2016, Clinical Cancer Research.

Immunoglobulin light chain kappa deletion rearrangement as a marker of clonality in mantle cell lymphoma.

F. Cavalli, M. Ghielmini, E. Zucca, 1999, Leukemia & lymphoma.

Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO).

F. Cavalli, R. Herrmann, A. Goldhirsch, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Low-dose continuous intravenous infusion of 5-fluorouracil for metastatic breast cancer.

F. Cavalli, A. Goldhirsch, G. Marini, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Marginal zone B-cell lymphoma: A clinical comparison of nodal and mucosa-associated lymphoid tissue types. Non-Hodgkin's Lymphoma Classification Project.

B. Nathwani, D. Weisenburger, J. Armitage, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical significance of follicular lymphoma with monocytoid B cells. Non-Hodgkin's Lymphoma Classification Project.

B. Nathwani, D. Weisenburger, J. Armitage, 1999, Human pathology.

Randomized trial of low- versus high-dose medroxyprogesterone acetate in the induction treatment of postmenopausal patients with advanced breast cancer.

F. Cavalli, A. Goldhirsch, P. Alberto, 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of the antipurine antifolate lometrexol (DDATHF) with folinic acid rescue.

F. Cavalli, C. Sessa, M. D’Incalci, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI.

F. Cavalli, R. Gelber, A. Goldhirsch, 1998, European journal of cancer.

Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group.

R. Bociek, F. Cavalli, S. Lade, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Population‐based outcome analysis of diffuse large B‐cell lymphoma in people living with HIV infection and competent individuals

F. Cavalli, M. Battegay, E. Bernasconi, 2018, Hematological oncology.

952PPATIENTS WITH HODGKIN'S LYMPHOMA HAVE A SIGNIFICANTLY BETTER OUTCOME IF TREATED WITHIN A CLINICAL TRIAL.

F. Cavalli, M. Ghielmini, A. Stathis, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Detection rate of fluorine‐18‐fluorodeoxyglucose positron emission tomography in patients with marginal zone lymphoma of MALT type: a meta‐analysis

F. Cavalli, L. Ceriani, E. Zucca, 2015, Hematological oncology.

Clinical activity of everolimus in relapsed/refractory marginal zone B‐cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group

F. Cavalli, G. Gaidano, P. Zinzani, 2014, British journal of haematology.

MALT Lymphoma (Extranodal Marginal Zone B-Cell Lymphoma)

F. Cavalli, E. Zucca, F. Bertoni, 2013 .

Activity of Rituximab in Extranodal Marginal Zone Lymphomas (MALT Type)

Frcp, F. Cavalli, G. Martinelli, 2002 .

Efficacy of alemtuzumab and gemcitabine in a patient with enteropathy‐type T‐cell lymphoma

F. Cavalli, L. Mazzucchelli, E. Zucca, 2008, British journal of haematology.

Role of radiotherapy in patients with early-stage diffuse large B-cell lymphoma of Waldeyer's ring in remission after anthracycline-containing chemotherapy

F. Cavalli, G. Gutiérrez-García, A. Rossi, 2013, Leukemia & lymphoma.

Original article: Sequential estrogen receptor determinations from primary breast cancer and at relapse: Prognostic and therapeutic relevance

F. Cavalli, A. Goldhirsch, M. Castiglione, 1992 .

Biased immunoglobulin genes rearrangement in mantle cell lymphoma: Hints to identify the normal B-cell counterpart

F. Cavalli, S. Cogliatti, D. Capello, 2011 .

Risk factors of central nervous system relapse in mantle cell lymphoma

F. Cavalli, M. Ghielmini, L. Mazzucchelli, 2013, Leukemia & lymphoma.

A phase II trial of bendamustine in combination with ofatumumab in patients with relapsed or refractory marginal zone B‐cell lymphomas

F. Cavalli, A. Stathis, E. Zucca, 2020, Hematological oncology.

Early progression of disease predicts shorter survival in patients with mucosa-associated lymphoid tissue lymphoma receiving systemic treatment

F. Cavalli, V. Torri, L. Cascione, 2020, Haematologica.

Clinical features, treatment and outcome in a series of 93 patients with low-grade gastric MALT lymphoma.

F. Cavalli, E. Pedrinis, A. Pascarella, 1997, Leukemia & lymphoma.

Evaluation of the Different Stratification Models for POD24 Prediction in Patients with Follicular Lymphoma

F. Cavalli, A. Valera, M. Ghielmini, 2020 .

Prospective Management of Primary Testicular Lymphoma (PTL) with Doxorubicin-Based Chemotherapy, Prophylactic Intrathecal (IT) Methotrexate and Radiotherapy (RT), but without Rituximab: Results from IELSG.

F. Cavalli, M. Gospodarowicz, G. Rassidakis, 2006 .

Toward a Risk-Tailored Therapeutic Policy in Mantle Cell Lymphoma

F. Cavalli, D. Rossi, E. Zucca, 2018, Current Oncology Reports.

In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas.

F. Cavalli, A. Valentini, D. Maccallum, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

A first-in-class Wiskott-Aldrich syndrome protein (WASp) activator with anti-tumor activity in hematological cancers

F. Cavalli, L. Cascione, A. Stathis, 2022, bioRxiv.

A Case of Hodgkin Lymphoma in a Patient with a History of Bone Pain and an Initial Diagnosis of Chronic Osteomyelitis

F. Cavalli, L. Mazzucchelli, A. Stathis, 2015, Tumori.

Phase II study of 5-Aza-2′-deoxycytidine in advanced ovarian carcinoma

F. Cavalli, C. Sessa, G. Stoter, 1990 .

Treatment and prognosis of centrocytic (mantle cell) lymphoma: a retrospective analysis of twenty-six patients treated in one institution.

F. Cavalli, E. Pedrinis, E. Zucca, 1994, Leukemia & lymphoma.

Phase II study of 5-aza-2'-deoxycytidine in advanced ovarian carcinoma. The EORTC Early Clinical Trials Group.

F. Cavalli, C. Sessa, G. Stoter, 1990, European journal of cancer.

Genome‐wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia

F. Cavalli, D. Rossi, G. Gaidano, 2011, British journal of haematology.

A randomized study of methotrexate, bleomycin, hydroxyurea with versus without cisplatin in patients with previously untreated and recurrent squamous cell carcinoma of the head and neck.

F. Cavalli, W. Lehmann, E. Kaplan, 1987, European journal of cancer & clinical oncology.

Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind, placebo-controlled study.

F. Cavalli, M. Aapro, W. Jungi, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I study of the combination of monthly carboplatin and weekly cisplatin.

F. Cavalli, A. Goldhirsch, G. Martinelli, 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

The global fight against cancer: challenges and opportunities

F. Cavalli, R. Atun, 2018, The Lancet.

Marginal Z one B -Cell L ymphoma: A C linical C omparison of N odal a nd M ucosa-Associate d L ymphoid T issue T ypes

B. Nathwani, D. Weisenburger, J. Armitage, 1999 .

Primary extranodal lymphoma of skeletal muscles: a report of four cases.

F. Cavalli, E. Zucca, F. Bertoni, 1998, Oncology reports.

Phase II trial of cis‐dichlorodiammineplatinum (II) in advanced malignant lymphoma: A study of the cancer and acute leukemia group B

F. Cavalli, T. Pajak, N. Nissen, 1981 .

Phase I trial of 4-demethoxydaunorubicin with single i.v. doses.

F. Cavalli, M. Varini, P. Togni, 1982, European journal of cancer & clinical oncology.

Phase-I trial of 4-demethoxydaunorubicin in acute leukaemias

F. Cavalli, C. Sessa, M. Fopp, 2004, Investigational new drugs.

Effect of age on the characteristics and clinical behavior of non-Hodgkin's lymphoma patients. The Non-Hodgkin's Lymphoma Classification Project.

Anderson, B. Nathwani, W. Chan, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Epirubicin in colorectal cancer. A phase II study of the early clinical trials group (EORTC).

F. Cavalli, H. Hansen, H. Høst, 1985, Investigational new drugs.

Phase II trial of 4'-deoxydoxorubicin in advanced non-small cell lung cancer.

F. Cavalli, C. Sessa, R. Joss, 1985, Cancer treatment reports.

ACUTE MYELOGENOUS LEUKAEMIA: MAINTENANCE CHEMOTHERAPY AFTER EARLY CONSOLIDATION TREATMENT DOES NOT PROLONG SURVIVAL

F. Cavalli, A. Gratwohl, P. Imbach, 1984, The Lancet.

Fine-needle aspiration to diagnose primary thyroid lymphoma: a systematic review and meta-analysis.

F. Cavalli, P. Trimboli, F. Giorgino, 2019, European journal of endocrinology.

Early-stage diffuse large B cell lymphoma of the head and neck: clinico-biological characterization and 18 year follow-up of 488 patients (IELSG 23 study)

F. Cavalli, G. Gutiérrez-García, A. Rossi, 2014, Annals of Hematology.

Baseline status of paediatric oncology care in ten low-income or mid-income countries receiving My Child Matters support: a descriptive study.

Eva Steliarova-Foucher, Ian Magrath, E. Steliarova-Foucher, 2008, The Lancet. Oncology.

Who benefitis from Phase I studies

F. Cavalli, C. Sessa, 1990 .

Phase II trial of cis-dichlorodiammineplatinum (II) in advanced malignant lymphoma: a study of the cancer and acute leukemia group B.

F. Cavalli, T. Pajak, N. Nissen, 1981, Cancer.

Lack of CD95/FAS gene somatic mutations in extranodal, nodal and splenic marginal zone B cell lymphomas

F. Cavalli, L. Baldini, A. Neri, 2000, Leukemia.

Follicular lymphoma: State‐of‐the‐art ICML workshop in Lugano 2015

B. Nadel, K. Tarte, R. Gascoyne, 2017, Hematological oncology.

Randomised comparison of complications from three different permanent central venous access systems.

F. Cavalli, P. Gertsch, M. Bogen, 2009, Swiss medical weekly.

Prognostic impact of monocyte count at presentation in mantle cell lymphoma

F. Cavalli, M. Ghielmini, Cassio Polpo de Campos, 2013, British journal of haematology.

Prognosis of Acute Myeloid Leukemia in the General Population: Data from Southern Switzerland

F. Cavalli, M. Ghielmini, A. Bordoni, 2009, Tumori.

Epidemiology and management of lymphoma in low‐income countries

F. Cavalli, A. Rohatiner, I. Magrath, 2011, Hematological oncology.

Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic–pharmacodynamic analysis from the IELSG no. 20 trial

F. Cavalli, S. Krähenbühl, M. Reni, 2010, British Journal of Cancer.

A Study of the Toxicity of Vindesine in Continuous Infusion over Five Days

F. Cavalli, M. Varini, M. Beer, 1981 .

Acute Myeloid Leukemia in the Elderly: Results of an Individualized Approach in Two Centres

F. Cavalli, V. Spataro, T. Kovacsovics, 2000, Leukemia & lymphoma.

Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trial

C. Copie-Bergman, C. Burton, F. Cavalli, 2009, British journal of haematology.

Asociación de Hemato‐Oncología Pediátrica de Centro América (AHOPCA): A model for sustainable development in pediatric oncology

F. Cavalli, R. Ribeiro, M. Valsecchi, 2014, Pediatric blood & cancer.

Activity of aphidicolin glycinate alone or in combination with cisplatin in a murine ovarian tumor resistant to cisplatin

F. Cavalli, M. Zucchetti, G. Tagliabue, 2004, Cancer Chemotherapy and Pharmacology.

An appeal to world leaders: stop cancer now

F. Cavalli, 2013, The Lancet.

PILLAR-2: A randomized, double-blind, placebo-controlled, phase III study of adjuvant everolimus (EVE) in patients (pts) with poor-risk diffuse large B-cell lymphoma (DLBCL).

F. Cavalli, M. Hino, T. Witzig, 2016 .

Hematotoxicity on human bone marrow- and umbilical cord blood-derived progenitor cells and in vitro therapeutic index of methoxymorpholinyldoxorubicin and its metabolites

F. Cavalli, M. Ghielmini, V. Torri, 1998, Cancer Chemotherapy and Pharmacology.

Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial

F. Cavalli, M. Ogura, M. Hino, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Management of non-Hodgkin lymphomas arising at extranodal sites.

F. Cavalli, E. Zucca, A. Gregorini, 2010, Therapeutische Umschau. Revue therapeutique.

Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma.

F. Cavalli, P. Zinzani, F. Merli, 2015, Blood.

Gastric mucosa-associated lymphoid tissue lymphomas: more than a fascinating model.

F. Cavalli, E. Zucca, E. Roggero, 1997, Journal of the National Cancer Institute.

Circulating tumor DNA as a liquid biopsy in plasma cell dyscrasias

F. Cavalli, M. Ghielmini, D. Rossi, 2018, Haematologica.

Flows and flaws in primary central nervous system lymphoma

F. Cavalli, E. Zucca, A. Ferreri, 2010, Nature Reviews Clinical Oncology.

Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma.

F. Cavalli, A. Harris, J. Baselga, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Identifying B reast C ancer P atients a t H igh R isk f or Bone M etastases

F. Cavalli, M. Bonetti, R. Gelber, 2000 .

Low-dose oral etoposide in epithelial cancer of the ovary.

F. Cavalli, M. Zucchetti, C. Sessa, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

Cancer prevention in the developing world: mission impossible?

F. Cavalli, 2008, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Clinical and pharmacokinetic study of oral NK611, a new podophyllotoxin derivative

F. Cavalli, M. Zucchetti, C. Sessa, 1996, Cancer Chemotherapy and Pharmacology.

Chronic oral etoposide in small-cell lung cancer: clinical and pharmacokinetic results.

F. Cavalli, V. Torri, M. Zucchetti, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

Interaction between route of intra-CSF chemotherapy administration and efficacy of therapy in patients wtih neoplastic meningitis.

F. Cavalli, T. Batchelor, M. Chamberlain, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial with Brequinar (DUP-785, NSC 368390) in patients with metastatic colorectal cancer: a study of the Early Clinical Trials Group of the EORTC.

F. Cavalli, G. Stoter, P. Dodion, 1990, Annals of oncology : official journal of the European Society for Medical Oncology.

Endocrine Therapy of Breast Cancer

F. Cavalli, 1986, ESO Monographs.

Quality-of-Life-Adjusted Evaluation of Adjuvant Therapies for Operable Breast Cancer

F. Cavalli, R. Gelber, A. Goldhirsch, 1991 .

Randomized trial of 3 different regimens of combination chemotherapy in patients receiving simultaneously a hormonal treatment for advanced breast cancer.

F. Cavalli, A. Goldhirsch, W. Jungi, 1983, European journal of cancer & clinical oncology.

Quality of life in postmenopausal patients with breast cancer after failure of tamoxifen: formestane versus megestrol acetate as second-line hormonal treatment. Swiss Group for Clinical Cancer Research (SAKK).

F. Cavalli, A. Goldhirsch, C. Hürny, 1999, European journal of cancer.

The best available adjuvant treatments are within the framework of clinical trials. The International Breast Cancer Study Group.

F. Cavalli, A. Goldhirsch, M. Castiglione, 1995, Israel journal of medical sciences.

Clinical and molecular determinants of survival in pancreatic cancer patients treated with second-line chemotherapy: results of an Italian/Swiss multicenter survey.

R. Labianca, F. Cavalli, C. Sternberg, 2007, Anticancer research.

Identifying breast cancer patients at high risk for bone metastases.

F. Cavalli, M. Bonetti, R. Gelber, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and clinical cross-resistance of a new combination therapy (AMSA/VP16) in previously treated patients with acute nonlymphocytic leukemia.

F. Cavalli, A. Gratwohl, V. V. von Fliedner, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant therapy in postmenopausal node-positive breast cancer.

M. Tattersall, F. Cavalli, R. Gelber, 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The masterclass of the european school of oncology: the 'key educational event' of the school.

F. Cavalli, R. Stahel, N. Pavlidis, 2010, European Journal of Cancer.

ESO's career development program (2002-2021): Presentation and evaluation.

F. Cavalli, M. Aapro, N. Pavlidis, 2021, Critical reviews in oncology/hematology.

The Contribution of the European School Of Oncology Education to the Central Asian and Caucasian Regions

F. Cavalli, M. Aapro, N. Pavlidis, 2021, Journal of Cancer Education.

Clinical Case Presentation and Discussion During ESO-ESMO Masterclass: a 10-Year Interactive Educational Experience

F. Cavalli, R. Stahel, M. Aapro, 2020, Journal of Cancer Education.

ESO-ESMO Masterclass in Clinical Oncology: Analysis and Evaluation of the Learning Self-Assessment Test

F. Cavalli, R. Stahel, M. Aapro, 2019, Journal of Cancer Education.

Changing the education paradigm in oncology: ESO masterclass, 17 years of continuous success.

F. Cavalli, R. Stahel, M. Aapro, 2019, Critical reviews in oncology/hematology.

Euro-Arab School of Oncology: an educational collaborative activity of the European School of Oncology with the Arab world.

F. Cavalli, Alberto Costa, N. Pavlidis, 2011, Journal of cancer education : the official journal of the American Association for Cancer Education.

Testicular cancer after treatment for Hodgkin's disease.

F. Cavalli, S. Kaplan, F. Camponovo, 1980, The New England journal of medicine.

Phase II trials with flavone acetic acid (NCS. 347512, LM975) in patients with advanced carcinoma of the breast, colon, head and neck and melanoma

F. Cavalli, M. Glabbeke, S. Monfardini, 2004, Investigational New Drugs.

Phase I-II study of escalating doses of amifostine combined with high-dose cyclophosphamide

F. Cavalli, M. Ghielmini, C. Sessa, 2001, Cancer Chemotherapy and Pharmacology.

Marginal zone lymphomas: Reconsidering similarities and differences while moving towards personalized treatment.

F. Cavalli, E. Zucca, A. Polliack, 2017, Best practice & research. Clinical haematology.

Primary mediastinal large B-cell lymphoma (PMLCL): the need for prospective controlled clinical trials.

F. Cavalli, E. Pedrinis, J. Bernier, 1999, Leukemia & lymphoma.

Phase II trial of diaziquone (AZQ) in advanced malignant melanoma.

F. Cavalli, M. van Glabbeke, H. Høst, 1983, European journal of cancer & clinical oncology.

Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma.

F. Cavalli, L. Cascione, P. Zinzani, 2018, Blood.

[Extrapulmonary small-cell carcinoma - a rarity with important therapeutic consequences].

F. Cavalli, W. Jungi, R. Joss, 1984, Schweizerische medizinische Wochenschrift.

[Morton's metatarsalgia].

F. Cavalli, F. Pollono, L. Tos, 1967, Minerva Ortopedica e Traumatologica.

Phase II study of diamino-dichlorophenyl-methylpyrimidine (DDMP) with folinic acid (CF) protection and rescue.

F. Cavalli, H. Hansen, A. Brugarolas, 1980, European Journal of Cancer.

Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days.

F. Cavalli, J. Wanders, J. Beijnen, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

Treatment and Prognosis of Centrocytic (Mantle Cell) Lymphoma: a Retrospective Analysis of Twenty-six Patients Treated in

F. Cavalli, E. Pedrinis, E. Zucca, 1994 .

A phase II study of carboplatin in advanced or metastatic stomach cancer.

F. Cavalli, M. van Glabbeke, S. Kaye, 1987, European journal of cancer & clinical oncology.

ENDOCRINE ADJUVANT THERAPY FOR BREAST CANCER

F. Cavalli, R. Gelber, A. Goldhirsch, 1985, The Lancet.

Short- or long-term chemotherapy for node-positive breast cancer: LMF 6 versus 18 cycles. SAKK study 27/76.

F. Cavalli, W. Jungi, K. Brunner, 1984, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Adjuvant chemotherapy in operable breast cancer: cyclophosphamide, methotrexate, and fluorouracil versus chlorambucil, methotrexate, and fluorouracil--11-year results of Swiss Group for Clinical Cancer Research trial SAKK 27/82.

F. Cavalli, M. Castiglione, H. Senn, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Analysis of Fas/CD95 gene somatic mutations in ovarian cancer cell lines

F. Cavalli, A. Codegoni, S. Carobbio, 2000, International journal of cancer.

A limited sampling model for the pharmacokinetics of etoposide given orally

F. Cavalli, V. Torri, M. Zucchetti, 2004, Cancer Chemotherapy and Pharmacology.

Phase I clinical and pharmacological study of oral methoxymorpholinyl doxorubicin (PNU 152243)

F. Cavalli, M. Ghielmini, M. Zucchetti, 1999, Cancer Chemotherapy and Pharmacology.

Prognostic S coring S ystem f or P rimary C NS L ymphomas: The I nternational E xtranodal L ymphoma S tudy G roup Experience

J. Blay, F. Cavalli, A. Rossi, 2003 .

Platinum dose-intensity in solid tumors: pharmacological and clinical perspectives.

F. Cavalli, C. Sessa, O. Pagani, 1995, Bulletin du cancer.

CGS 16949A, a new aromatase inhibitor in the treatment of breast cancer--a phase I study.

F. Cavalli, A. Goldhirsch, A. Bhatnagar, 1990, Annals of oncology : official journal of the European Society for Medical Oncology.

In Vitro Activity of SYK and BCR-ABL Inhibitors in Aggressive Lymphomas.

F. Cavalli, G. Pruneri, G. Gaidano, 2006 .

A Combination of Cyclophosphamide, Methotrexate, Vincristine and VP 16–213 (NSC 141 540) in the Treatment of Bronchogenic Carcinoma

F. Cavalli, K. Brunner, R. Sonntag, 1977, Tumori.

Phase II evaluation of bisantrene in metastatic breast cancer.

F. Cavalli, M. Rozencweig, W. W. ten Bokkel Huinink, 1985, Cancer treatment reports.

The World Cancer Declaration: a roadmap for change.

F. Cavalli, 2008, The Lancet. Oncology.

Towards a global cancer fund.

F. Cavalli, R. Atun, 2015, The Lancet. Oncology.

The Importance of Age in Prognosis of Follicular Lymphoma: Clinical Features and Life Expectancy of Patients Younger Than 40 Years

A. López-Guillermo, S. Montoto, E. Montserrat, 2011 .

Combination chemotherapy for non-small cell lung cancer with doxorubicin and mitomycin or cisplatin and etoposide.

F. Cavalli, A. Goldhirsch, R. Joss, 1984, Cancer treatment reports.

The last 3 months of life of cancer patients: Medical aspects and role of home-care services in southern Switzerland

F. Cavalli, M. Ghielmini, C. Sessa, 1996, Supportive Care in Cancer.

A randomized crossover clinical study on the effectiveness of L-sulpiride in the prevention of nausea and emesis induced by antiblastic chemotherapy

F. Cavalli, L. Bonollo, A. Martini, 1989 .

START: a European state-of-the-art on-line instrument for clinical oncologists.

F. Cavalli, F. D. De Braud, P. Bruzzi, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Stage-modi ¢ ed international prognostic index e ¡ ectively predicts clinical outcome of localized primary gastric di ¡ use large B-cell lymphoma

F. Cavalli, T. Barbui, A. Rossi, 1999 .

Mass spectrometric identification and analysis of some aphidicolin metabolites in cancer patients.

F. Cavalli, M. Zucchetti, R. Fanelli, 1993, Biological mass spectrometry.

Interferons in oncology: current status and future directions.

F. Cavalli, A. Kimchi, F. Balkwill, 1987, European journal of cancer & clinical oncology.

Management of rare forms of lymphoma

F. Cavalli, E. Zucca, F. Bertoni, 1998, Current Opinion in Oncology.

Initial prognostic factors in small-cell lung cancer patients predicting quality of life during chemotherapy. Swiss Group for Clinical Cancer Research (SAKK).

F. Cavalli, R. Stahel, C. Hürny, 1996, British Journal of Cancer.

Ibrutinib dose intensity in high‐risk chronic lymphocytic leukemia

F. Cavalli, D. Rossi, G. Gaidano, 2022, Hematological Oncology.

Cytoplasmatic Expression of CD34 in Acute Leukemia

F. Cavalli, M. Uhr, P. Tamasy, 1998 .

Prognostic models for diffuse large b‐cell lymphoma

F. Cavalli, E. Pedrinis, E. Zucca, 2000, Hematological oncology.

Live European School of Oncology e-Sessions (e-ESO).

F. Cavalli, M. Aapro, Alberto Costa, 2021, Critical reviews in oncology/hematology.

Clinical characteristics of vulnerable populations hospitalized and diagnosed with COVID-19 in Buenos Aires, Argentina

S. Kochen, F. Cavalli, P. Salgado, 2021, Scientific Reports.

Phase II studies of 4'-iodo-4'-deoxydoxorubicin in advanced non-small cell lung, colon and breast cancers.

F. Cavalli, C. Sessa, S. Kaye, 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

METABOLIC HETEROGENEITY OF BASELINE 18‐FDG PET‐CT SCAN PREDICTS OUTCOME IN PRIMARY MEDIASTINAL B‐CELL LYMPHOMA.

F. Cavalli, L. Ceriani, M. Martelli, 2017 .

First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88.

F. Cavalli, A. Goldhirsch, B. Thürlimann, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the ‘cutaneous variant’ 1

A. López-Guillermo, E. Campo, F. Cavalli, 2022 .

IMPACT OF DIFFERENT INDUCTION REGIMENS ON THE OUTCOME OF PRIMARY MEDIASTINAL B CELL LYMPHOMA IN THE PROSPECTIVE IELSG 37 TRIAL

F. Cavalli, F. Angrilli, F. Merli, 2021, Hematological Oncology.

Role of angiogenesis inhibitors in acute myeloid leukemia.

F. Cavalli, D. Hossfeld, U. Dührsen, 2001, Cancer journal.

Randomized Phase II Trial on Primary Chemotherapy with High-Dose Methotrexate Alone or Associated with High-Dose Cytarabine for Patients with Primary CNS Lymphoma (IELSG #20 Trial): Tolerability, Activity and Event-Free Survival Analysis

F. Cavalli, A. Brandes, H. Gómez, 2008 .

TCNU (LS 2667), a new active drug in the treatment of advanced colorectal cancer. EORTC Early Clinical Trials Group.

F. Cavalli, P. Dombernowsky, S. Gundersen, 1989, European Journal of Cancer and Clinical Oncology.

Phase I trial of 1,2,4-triglycidylurazol (TGU, NSC 332488): a new triepoxide cytostatic agent.

F. Cavalli, H. Hansen, S. W. Hansen, 1985, European journal of cancer & clinical oncology.

Potential Pathogenetic Role of Achromobacter (Alcaligenes) Xylosoxidans in Primary Extranodal Marginal Zone Lymphoma of the Lung (BALT-Lymphoma): Update of the Results of a Retrospective Analysis on Behalf of IELSG

D. Weisenburger, J. Armitage, F. Cavalli, 2011 .

Primary mediastinal B‐cell lymphoma

P. Gaulard, F. Cavalli, S. Pileri, 2007, Hematological oncology.

A phase II study of spirogermanium in patients with advanced malignant lymphoma

F. Cavalli, C. Sessa, R. Joss, 1989, Investigational New Drugs.

A phase I trial of marcellomycin with a weekly dose schedule.

F. Cavalli, A. Goldhirsch, M. Varini, 1983, European journal of cancer & clinical oncology.

leukemia: cancer and leukemia group B studies Combination chemotherapy for terminal-phase chronic granulocytic

F. Cavalli, K. Rai, R. Silver, 2011 .

“Fatigue and malaise” as a quality-of-life indicator in small-cell lung cancer patients

F. Cavalli, C. Hürny, J. Bernhard, 1993, Supportive Care in Cancer.

Bacteria-eradicating therapy for ocular adnexal MALT lymphoma: questions for an open international prospective trial.

F. Cavalli, J. Radford, C. Doglioni, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Primary Diffuse Large B-Cell Lymphoma of the Testis (PTL): A Prospective Study of Rituximab (R)-CHOP with CNS and Contralateral Testis Prophylaxis. Results of the IELSG 10 Study.

A. López-Guillermo, F. Cavalli, H. Gómez, 2006 .

Prevalence of Helicobacter pylori and hepatitis C virus infections among non-Hodgkin's lymphoma patients in Southern Switzerland.

F. Cavalli, E. Pedrinis, E. Zucca, 2000, Haematologica.

Microsatellite instability in gastric MALT lymphomas and other associated neoplasms.

F. Cavalli, R. Cerutti, E. Zucca, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue.

A. López-Guillermo, E. Campo, F. Cavalli, 2003, Blood.

Detection rate of fluorine‐18‐fluorodeoxyglucose positron emission tomography in patients with marginal zone lymphoma of MALT type: a meta‐analysis

F. Cavalli, L. Ceriani, E. Zucca, 2015, Hematological oncology.

Interferon alfa-2b with VMCP compared to VMCP alone for induction and interferon alfa-2b compared to controls for remission maintenance in multiple myeloma: interim results.

F. Cavalli, H. Senn, H. Ludwig, 1991, European journal of cancer.

Deregulation of ETS1 and FLI1 contributes to the pathogenesis of diffuse large B-cell lymphoma.

W. Chan, T. Greiner, F. Cavalli, 2013, Blood.

Functional Imaging Using 18-Fluorodeoxyglucose PET in the Management of Primary Mediastinal Large B-Cell Lymphoma: The Contributions of the International Extranodal Lymphoma Study Group.

F. Cavalli, L. Ceriani, E. Zucca, 2016, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Randomized phase 3 study of rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in newly diagnosed mantle cell lymphoma (MCL) patients (pts) ineligible for bone marrow transplantation (BMT).

F. Cavalli, T. Robak, H. Velde, 2014 .

Histologic transformation in marginal zone lymphomas†.

F. Cavalli, L. Mazzucchelli, G. Gaidano, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma.

F. Cavalli, P. Zinzani, F. Merli, 2015, Blood.

A RANDOMIZED TRIAL OF OBSERVATION VERSUS RADIOTHERAPY IN PRIMARY MEDIASTINAL B‐CELL LYMPHOMA PATIENTS WITH COMPLETE METABOLIC RESPONSE AFTER STANDARD IMMUNOCHEMOTHERAPY

F. Cavalli, F. Merli, A. Guarini, 2023, Hematological Oncology.

The International (Ludwig) Breast Cancer Study Group Trials I-IV: 15 years follow-up.

J. Forbes, F. Cavalli, R. Gelber, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II trial of cis‐dichlorodiammineplatinum (II) in advanced malignant lymphoma: A study of the cancer and acute leukemia group B

F. Cavalli, T. Pajak, N. Nissen, 1981, Cancer.